Zydus Lifesciences Ltd.

Cadila Healthcare is looking to raise at least Rs 150 crore via 5 years bond with call option after 3 years via book building at a semi-annual coupon of 9.60-9.70 percent. The issue opens and closes today and the bonds have been rated ‘AA+’ by CRISIL. Credit Agricole and SBI Capital Markets are arrangers to the deal.

Recently, Cadila Healthcare had received a warning notice from the US health regulator for violation of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals at its facility in Gujarat. The Gujarat Plant was inspected by USFDA between January 17 and February 3, 2011, and reviewed the firm's response to its observations on February 10, 2011, and noted that it lacks sufficient corrective actions.

Cadila Pharmaceuticals focuses on various areas, such as formulations (human & veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.